The relationship between plasma t-PA and PAI-1 levels is dependent on epistatic effects of the ACE I/D and PAI-1 4G/5G polymorphisms

Clinical Genetics

Volumn 62, Issue 1, 2002, Pages 53-59

  Moore, Jason H ^a   Smolkin, M E ^a   Lamb, J M ^a   Brown, N J ^a   Vaughan, D E ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Combinatorial partitioning method; Correlation; Epistasis; Fibrinolytic system; Gene gene interaction; Reninangiotensin system

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; CAUCASIAN; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FIBRINOLYSIS; GENE DELETION; GENE INSERTION; GENE LOCUS; GENETIC EPISTASIS; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MALE; NEGRO; PRIORITY JOURNAL; PROTEIN INTERACTION; RACE DIFFERENCE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SEX DIFFERENCE; THROMBOGENESIS;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; CHI-SQUARE DISTRIBUTION; EPISTASIS, GENETIC; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; TISSUE PLASMINOGEN ACTIVATOR;

INSERTION SEQUENCES;

EID: 0036665064     PISSN: 00099163     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0004.2002.620107.x     Document Type: Article

References (32)

1. Higgins MW, Luepker RV. Trends and determinants of coronary heart disease mortality: International comparisons. Int J Epidemiol 1989: 18 (Suppl. 1): 3.
2. American Heart Association. 1994 heart and stroke facts: 1994 statistical supplement. Dallas, TX: American Heart Association National Center, 1994.
3. Gotto AM Jr, Farmer JA. Risk factors for coronary artery disease. In: Braunwald E, ed. Heart disease. A textbook of cardiovascular medicine. Verstraete M, Flister V, Topol EJ, eds. Philadelphia: WB. Saunders Company, 1988: 1153-1190.
4. Lijnen RH, Collen D, Verstraete M. Thrombolytic agents. In: Cardiovascular thrombosis: thrombocardiology and thromboneurology, 2nd edn. Verstraete M, Flister V, Topol EJ, eds. Philadelphia: Lippincott-Raven Publishers, 1998: 301-320.
5. Harker LA, Mann KG. Thrombosis and fibrinolysis. In: Cardiovascular thrombosis: thrombocardiology and thromboneurology, 2nd edn. Philadelphia: Lippincott-Raven Publishers, 1998: 3-22.
6. Pennica D, Holmes WE, Kohr WJ et al. Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. Nature 1983: 301: 214-221.
7. Vaughan DE. Angiotensin, fibrinolysis, and vascular homeostasis. Am J Cardiol 2001: 87: 18C-24C.
8. Brown NJ, Agirbasli MA, Williams GH, Litchfield WR, Vaughan DE. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. Hypertension 1998: 32: 965-971.
9. Brown NJ, Gainer JV, Stein CM, Vaughan DE. Bradykinin stimulates tissue plasminogen activator release in human vasculature. Hypertension 1999: 33: 1431-1435.
10. Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealey JE, Laragh JH. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991: 324: 1098-1104.
11. Moore JH, Lamb JM, Brown, NJ. Vaughan DE. A comparison of combinatorial partitioning and linear regression for the detection of epistatic effects of the ACE I/D and PAI-1 4G/5G polymorphisms on plasma PAI-1 levels. Clin Genet 2002: 62: 74-79.
12. Ridker PM, Vaughan DE, Stampfer MJ et al. Baseline fibrinolytic state and the risk of future venous thrombosis. A prospective study of endogenous; tissue-type plasminogen activator and plasminogen activator inhibitor. Circulation 1992: 85: 1822-1827.
13. Shapiro SS, Wilk MB. An analysis of variance test for normality (complete samples). Biometrika 1965: 52: 591-611.
14. Royston JP. An extension of Shapiro and Wilk's W test for normality to large samples. Appl Stat 1982: 31: 115-124.
15. Box GEP, Cox DR. An analysis of transformations. J R Stat Soc Series B 1964: 26: 211-243.
16. Sokal RR, Rohlf FJ. Biometry. New York: W.H. Freeman, 1995.
17. Nelson MR, Kardia SLR, Ferrell RE, Sing CF. A combinatorial partitioning method to identify multilocus genotypic partitions that predict quantitative trait variation. Genome Res 2001: 11: 458-470.
18. Weiss KG. Genetic variation and human disease. Cambridge: Cambridge University Press, 1993.
19. Matsubara Y, Murata M, Isshiki I et al. Genotype frequency of plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism in healthy Japanese males and its relation to PAI-1 levels. Int J Hematol 1999: 69: 43-47.
20. Magnus P, Maartmann-Moe K, Golden W, Nance WE, Berg K. Genetics of the low density lipoprotein receptor. II. Genetic control of variation in cell membrane low density lipoprotein receptor activity in cultured fibroblasts. Clin Genet 1981: 20: 104-112.
21. Berg K. Variability gene effect on cholesterol at the Kidd blood group locus. Clin Genet 1988: 33: 102-107.
22. Reilly SL, Ferrell RE, Kottke BA, Kamboh MI, Sing CF. The gender-specific apolipoprotein E genotype influence on the distribution of lipids and apolipoproteins in the population of Rochester, MN. I. Pleiotropic effects on means and variances. Am J Hum Genet 1991: 49: 1155-1166.
23. Haviland MB, Lussier-Cacan S, Davignon J, Sing CF. Impact of apolipoprotein E genotype variation on means, variances, and correlations of plasma lipid, lipoprotein, and apolipoprotein traits in octogenarians. Am J Med Genet 1995: 58: 315-331.
24. Nelson MR, Kardia SL, Ferrell RE, Sing CF. Influence of apolipoprotein E genotype variation on the means, variances, and correlations of plasma lipids and apolipoproteins in children. Ann Hum Genet 1999: 63: 311-328.
25. Reilly SL, Ferrell RE, Sing CF. The gender-specific apolipoprotein E genotype influence on the distribution of plasma lipids and apolipoproteins in the population of Rochester, MN. III. Correlations and covariances. Am J Hum Genet 1994: 55: 1001-1018.
26. Moore JH. Improved power of sib-pair linkage analysis using measures of complex trait dynamics. Hum Hered 2001: 52: 113-115.
27. Moore JH, Williams SM. New strategies for identifying gene-gene interactions in hypertension. Ann Med 2002: 34: 1-8.
28. Brown NJ, Murphey LJ, Srikuma N, Koschachuhanan N, Williams GH, Vaughan DE. Interactive effect of PAI-1 4G/5G genotype and salt intake on PAI-1 antigen. Arterioscler Thromb Vasc Biol 2001: 21: 1071-1077.
29. Ridker PM, Gaboury CL, Conlin PR, Seely EW, Williams GH, Vaughan DE. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation 1993: 87: 1969-1973.
30. Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation 1997: 95: 1115-1118.
31. Lindahl TL, Ohlsson PI, Wiman B. The mechanism of the reaction between human plasminogen-activator inhibitor 1 and tissue plasminogen activator. Biochem J 1990: 265: 109-113.
32. Ritchie MD, Hahn LW, Roodi N et al. Multifactor dimensionality reduction reveals high-order interactions among estrogen metabolism genes in sporadic breast cancer. Am J Hum Genet 2001: 69: 138-147.